Business ❯ Pharmaceutical Industry ❯ Market Trends

Drug Pricing

Insurance Coverage Novo Nordisk Revenue Projections Generic Drug Launches Generic Medications Obesity Medications Investment Eli Lilly and Novo Nordisk Cost of Medications Valuation Metrics Insulin Manufacturing Generic Drugs Alternative Medications Economic Impact Counterfeit Drug Market Generic Competition Consumer Access

Novo’s New GLP‑1 Pill Tests Lilly’s Lead as Investors Eye Pfizer’s Cheaper Shares

Lilly’s premium price meets a new oral challenger in the GLP‑1 race.

Eli Lilly to Acquire Ventyx Biosciences for $1.2 Billion in Bet on Oral NLRP3 Drugs

Takeda’s AI-Assisted Psoriasis Pill Succeeds in Phase 3, Outperforms Otezla